$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
瑞格非尼为中晚期肝癌患者带来新的希望
2025-10-19 11:44:20
Check Details
多吉美治疗肝癌的推荐剂量
2025-10-19 11:44:20
Check Details
瑞格非尼适应于多吉美耐药的肝癌患者
2025-10-19 11:44:20
Check Details
索拉非尼治疗乙肝肝癌患者效果如何?
2025-10-19 11:44:20
Check Details
瑞格非尼治疗多吉美耐药的肝癌患者
2025-10-19 11:44:20
Check Details
索拉非尼治疗亚太地区晚期肝癌患者疗效
2025-10-19 11:44:20
Check Details
索拉非尼晚期难治性实体瘤四项I期试验综述
2025-10-19 11:44:20
Check Details
索拉非尼治疗亚洲晚期肝癌患者的疗效
2025-10-19 11:44:20
Check Details
瑞格非尼用于治疗多吉美治疗后耐药的肝癌患者
2025-10-19 11:44:20
Check Details
多吉美显著延长肝癌患者的生存时间
2025-10-19 11:44:20
Check Details
仑伐替尼使中国HBV相关肝癌患者获益
2025-10-19 11:44:20
Check Details
瑞格非尼治疗多吉美治疗后耐药肝癌患者
2025-10-19 11:44:20
Check Details
1
2
...
2564
2565
2566
2567
2568
2569
2570
...
4156
4157
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
2
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
3
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
4
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
5
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
6
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
7
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice
8
Managing Amivantamab Infusion Reactions: A Clinical Guide for International Practice
9
Onset Timeline and Efficacy Assessment of Margetuximab plus Chemotherapy in HER2-Positive Metastatic Breast Cancer
10
Avutometinib Plus Defactinib: A Precision Therapy for KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer
11
Vemurafenib (Zelboraf) Complete Medication Guide
12
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice